You are here

TİYOTROPİYUMUN OBSTRÜKTİF AKCİĞER HASTALIKLARI ÜZERİNE ETKİLERİ

THE EFFECTS OF TIOTROPIUM ON OBSTRUCTIVE AIRWAY DISEASES

Journal Name:

Publication Year:

Keywords (Original Language):

Abstract (2. Language): 
Aim: To assess the role of tiotropium on obstructive airway diseases. Main findings: Tiotropium is a novel, once-daily inhaled anticholinergic bronchodilator. Its effect persists more than 24 hours due to M3 muscarinic receptor blockade. Tiotropium increases vital capacity, inspiratory capacity, and tidal volume whereas decreases residual volume, and functional residual capacity. The relief of dyspnea is common in patients with chronic obstructive pulmonary disease because the reduction in hyperinflation by the drug. Patients receiving tiotropium have been experienced 20 to 30 % fewer exacerbations than they receiving placebo or ipratropium. The annual loss of FEV1 (Forced Expiratory Volume in 1 second) may be restored by tiotropium. Conclusions: It seems that tiotropium is a good drug for long-term treatment for stable chronic obstructive pulmonary disease.
Abstract (Original Language): 
Amaç: Tiyotropiyumun obstrüktif akciğer hastalıklarındaki rolünü değerlendirmek. Ana bulgular: Tiyotropiyum günde tek doz kullanılan yeni bir inhale antikolinerjik bronkodilatatördür. Etkisi M3 muskarinik reseptör blokajına bağlı olarak 24 saatten uzun sürer. Tiyotropiyum vital kapasiteyi, inspiratuar kapasiteyi ve soluk hacmini arttırırken rezidüel volüm ve fonksiyonel rezidüel kapasiteyi azaltmaktadır. İlaç aşırı şişkinliği azalttığından kronik obstrüktif akciğer hastalığı olan hastalarda nefes darlığının iyileşmesi olağandır. Tiyotropiyum alan olgular, çalışmalarda plasebo veya ipratropiyum alanlara göre % 20-30 oranında daha az alevlenme geçirmektedir. Yıllık FEV1 (1.saniyedeki zorlu ekspiratuar hacim) kaybı tiyotropiyum ile düzelebilmektedir. Sonuç: Tiyotropiyum stabil kronik obstrüktif akciğer hastalığının uzun süreli tedavisinde iyi bir ilaç gibi durmaktadır.

REFERENCES

References: 

1. Gross NJ. Anticholinergic agents in asthma and
COPD. Eur J Pharmacol, 2006; 533: 36-9.
2. Casaburi R, Briggs DD jr, Donohue JF, Serby CW,
Menjoge SS, Witek TJ jr. The spirometric efficacy of
once-daily dosing with tiotropium in stable COPD.
A 13-week multicenter trial. Chest, 2000; 118:
1294-302.
3. Gross NJ. Tiotropium bromide. Chest, 2004; 126:
1946-53.
4. Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ, Dutch Study Group. Tiotropium bromide,
a new long-acting antimuscarinic bronchodilator: a
pharmacodynamic study in patients with chronic
obstructive pulmonary disease (COPD). Eur Respir J,
1995; 8: 1506-13.
5. Briggs DD jr, Covelli H, Lapidus R, Bhattycharya S,
Kesten S, Cassino C. Improved daytime spirometric
efficacy of tiotropium compared with salmeterol in
patients with COPD. Pulm Pharmacol Ther, 2005;
18: 397-404.
6. Gross NJ, Skorodin MS. Role of the parasympathetic
system in airway obstruction due to emphysema. N
Engl J Med, 1984; 311: 421-5.
7. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper
JA jr, Korducki L, et al. Prevention of exacerbations
of chronic obstructive pulmonary disease with
tiotropium, a once-daily inhaled Anticholinergic
bronchodilator: a randomized trial. Ann Intern Med,
2005; 143: 317-26.
8. Celli B, ZuWallack R, Wang S, Kesten S. Improvement
in resting inspiratory capacity and hyperinflation
with tiotropium in COPD patients with increased
static lung volumes. Chest, 2003; 124: 1743-8.
9. Brusasco V, Hodder R, Mitravilles M, Korducki L,
Towse L, Kesten S. Health outcomes following
treatment for six months with once daily tiotropium
compared with twice daily salmeterol in patients
with COPD. Thorax, 2003; 58: 399-404.
10. Vincken W, van Noord JA, Greenhorst AP, Bantje
TA, Kesten S, Korducki L, et al. Improved health
outcomes in patients with COPD during 1 year’s
treatment with tiotropium. Eur Respir J, 2002; 19:
209-16.
11. Celli B, ZuWallack R, Wang S, Kesten S. Improvement
in resting inspiratory capacity and hyperinflation
with tiotropium in COPD patients with increased
static lung volumes. Chest, 2003; 124: 1743-8.
12. Gonlugur U. The effect of tiotropium on the pulmonary diffusing capacity. Methods Find Exp Clin
Pharmacol. 2007; 29: 535-7.
13. Dusser D, Bravo ML, Iacono P, MISTRAL study
group. The effect of tiotropium on exacerbations
and airflow in patients with COPD. Eur Respir J,
2006; 27: 547-55.
14. Anthonisen NR, Connett JE, Kiley JP. Effects of
smoking intervention and the use of an inhaled Anticholinergic bronchodilator on the rate of decline
of FEV1. The Lung Health Study. JAMA, 1994; 272:
1497-505.
15. Casaburi R, Mahler DA, Jones PW, Wanner A, San
PG, ZuWallack RL et al. A long-term evaluation of
once-daily inhaled tiotropium in chronic obstructive
pulmonary disease. Eur Respir J, 2002; 19: 217-24.
16. Friedman M, Serby CW, Menjoge SS, Wilson JD,
Hilleman DE, Witek TJ jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol
compared to ipratropium alone and albuterol alone
in chronic obstructive pulmonary disease. Chest,
1999; 115: 635-41.
17. Briggs DD jr, Covelli H, Lapidus R, Bhattycharya S,
Kesten S, Cassino C. Improved daytime spirometric
efficacy of tiotropium compared with salmeterol in
patients with COPD. Pulm Pharmacol Ther, 2005;
18: 397-404.
18. Vichyanond P, Sladek WA, Sur S, Hill MR, Szefler SJ,
Nelson HS. Efficacy of atropine methylnitrate alone
and in combination with albuterol in children with
asthma. Chest, 1990; 98: 637-42.
19. Ullah MI, Newman GB, Saunders KB. Influence of
age on response to ipratropium and salbutamol in
asthma. Thorax, 1981; 36: 523-9.
20. Jalobe OM. Asthma vs non-specific reversible airflow obstruction: clinical features and responsiveness to anticholinergic drugs. Respiration, 1984; 45:
237-42.
21. Gönlügür TE, Gönlügür U. Havayollarında kolinerjik
mekanizmalar.Turkiye Klinikleri J Med Sci 2007; 27:
610-4.

Thank you for copying data from http://www.arastirmax.com